Scott Gottlieb adds one more high-profile board seat to the post-FDA resume. And it’s another plum assignment
Scott Gottlieb has landed another high-profile board seat.
The revolving door out of the FDA led Gottlieb back to the American Enterprise Institute and his role as a partner at the big VC New Enterprise Associates. Then he quickly landed on the board of Pfizer and a real-world evidence player called Aetion. The FasterCures board run by ex-con philanthropist Michael Milken beckoned.
Now he’s adding Illumina to the roster. The DNA sequencing specialist $ILMN has been under pressure with weakened consumer test numbers in January, but it still has a market cap of $44 billion and close ties to Big Pharma players like Roche, which recently signed on for an alliance.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.